Rheumatology: Current Research
Open Access
ISSN: 2161-1149 (Printed)
ISSN: 2161-1149 (Printed)
Liubov Gargaun
Scientific Tracks Abstracts: Rheumatology & Orthopedics
N SAIDs are well-tolerated, however, considering their widespread use, clinicians continue to face the significant challenge of their serious side-effects associated with reduced prostaglandin E2 (PGE2). PGE2 plays physiological roles in gastrointestinal, renal and other systems and reducing levels of PGE2 in NSAID treatment may cause gastroduodenal ulcers, hypertension, and other side-effects. Unreduced PGE2 levels during NSAID treatment could prevent or mitigate these serious side-effects. Pyridine derivatives (PDs) have been found to modulate biosynthesis of PGE2. Some of them, mostly non- expensive drugs, such as nicotine, nicotinic acid, nicotinyl alcohol, pyridinol carbamate, pyridoxine hydrochloride, niceritrol and pyridostigmine bromide increase levels of endogenous PGE2. Based on Student�s t-test statistical analysis, as performed by us, of data extracted from unrelated peer-reviewed publications of studies involving NSAIDs, PGE2 and PDs completed in vitro and on healthy volunteers (Takahashi, H., 2007; Takahashi, H., 2006; Nozaki, S., 1987; Sahin, I., 1984; Eklund, B., 1979), we found and demonstrated that increased levels of PGE2 by the abovementioned PDs were not reduced by NSAIDs (COX1- and COX2- inhibitors) below physiological levels. This effect was missed by publications� authors. Modulation of biosynthesis of PGE2 in NSAIDs treatment is a novel concept that we are proposing and use of PDs can serve as proof of the mechanism and may offer a new promising cost-effective method to accomplish the high unmet medical need in prevention or mitigation of suppressing side-effect of NSAIDs (COX1- and COX2-inhibitors) on PGE2. Although the use of NSAIDs and PDs may have been described, it has not been observed before that modulation of biosynthesis of PGE2 by PDs does not allow NSAIDs to reduce PGE2 levels below physiological levels
Liubov Gargaun has completed her MD with Honours from State Medical University, Moldova. She worked as Chief of Internal Medicine Department and simultaneously as professor assistant of the Clinical Pharmacology Department. She undertook postdoctoral research at Iasi Medical University, Romania. In Canada Dr. L. Gargaun achieved a position as a Medical Advisor in a drug company. Currently, she is the Medical Development Director of Selag Inc., a Canadian healthcare research and consulting service organization. Her combined experience in academic, clinical practice and research, drug development and pharm industry allowed her to publish more than 10 publications in reputed journals and conference materials